



TAPIMMUNE

TapImmune Inc. ("TapImmune" "TPIV") is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. TPIV technologies are based on an understanding of the function of a unique protein "pump" known as TAP. **Transporters Associated with Antigen Processing (TAP)** are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. These markers are required for the effective recognition and **destruction of cancer cells** and virus infected cells by the immune system.

As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines. TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses. Therefore, we envisage establishing multiple collaborative partnerships as we progress gene-based TAP development and research in the clinic.

Clinical studies to date have identified a large number of cancers deficient in TAP including but not limited to **melanoma, lung, prostate, breast and ovarian cancer**. **TapImmune** believes these tumors would be responsive to the TAP therapeutic vaccine. In preclinical trials for melanoma and lung carcinoma, **animal survival rates of 70% were achieved using TAP vaccine therapy and 100% survival when TAP was administered ex-vivo**.

TPIV's vaccine has shown effective restoration of TAP and the TAP molecule also works to enhance targeted vaccines against infectious diseases. Including TAP in the much studied Smallpox Vaccine, its **potency was increased by 100-1000 times**. TPIV is currently developing models for the application of this technology for some of the most important societal pathogens with world class organizations including the Mayo Clinic and Aeras Global TB Foundation.

This is a new paradigm and the next logical step in the treatment of cancer and infectious diseases and could **significantly advance** the development of new vaccines as well as improve those that already exist.

Recent Highlight and Milestones Include:

- TB Vaccine Program with Aeras.
- Breast Cancer Clinical Trial (Her2Neu) Approved by FDA to start with Mayo Clinic Q1 2012
- Novel smallpox antigens plus TAP technology being tested in collaboration with Mayo Clinic
- Mark Reddish joins TPIV as VP Product Development.
- State of the Art Facility in Seattle opened in Jan 2012.

The global vaccine market is over \$21 billion.

The TapImmune cancer vaccine is a stand alone product that also complements many current and promising vaccine targets, as well as the traditional area of immunotherapeutics.

TAP uniquely stimulates the NATURAL KILLERS in the immune system to destroy cancer cells.

TapImmune's Infectious disease vaccine immunotherapy can make prophylactic and bio-defense vaccines 100 times more effective!

TAP expression vectors represent the next logical step in development of more effective immunotherapies.

In The Media
BusinessWeek

Developments to Watch:
Waking Up a Sleeping Anticancer Gene

Popular Mechanics

Attacking Cancer - an Immune-Boosting Vaccine



Visit www.TapImmune.com to view and read these Media Releases



OTCBB – TPIV

Shares Authorized - 150 Million
Outstanding Shares: 52,000,000
Free Trading Float = 22 Million
Management Ownership: 17%
Affiliates and Management: 35%

Website: www.TapImmune.com

Contact:
Email: IR@TapImmune.com
Tel: (206) 336-5560

TapImmune Inc.
1551 Eastlake Avenue East
Seattle WA 98102

Glynn Wilson – Chairman & CEO
gwilson@tapimmune.com

Denis Corin - President & CFO
dcorin@tapimmune.com

Mark Reddish – VP Product Dev
mreddish@tapimmune.com

